SFM
VIVO

Signet Financial Management’s Meridian Bioscience Inc VIVO Stock Holding History

Signet Financial Management’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,883
Closed -$38K – 1448
2021
Q4 		$38K Buy
+1,883
New +$36.1K 0.01% 590

Other funds holding VIVO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Impactive Capital New York City, New York $1.38B AUM 1.92% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VLKIM
Van Lanschot Kempen Investment Management Amsterdam, Netherlands $11.4B AUM 16.77% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Signet Financial Management's VIVO Position: Q1 2022 in Review

Signet Financial Management sold out of Meridian Bioscience Inc (VIVO) in Q1 2022, closing a stake of 1,883 shares — an estimated $38K sold.

Signet Financial Management first reported a position in VIVO in Q4 2021 and held it in 1 quarter. The position peaked at $38K in Q4 2021. 210 funds tracked by Wall St. Rank hold VIVO as of Q1 2022.

  • Signet Financial Management reported no remaining Meridian Bioscience Inc position as of Q1 2022 after selling out during the quarter.
  • Signet Financial Management sold 1,883 Meridian Bioscience Inc shares in Q1 2022, an estimated $38K.
  • Signet Financial Management first reported a position in Meridian Bioscience Inc in Q4 2021 and held it in 1 quarter.
  • Signet Financial Management's Meridian Bioscience Inc position peaked at $38K in Q4 2021.
  • 210 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2022.

Based on Signet Financial Management's 13F filing for Q1 2022, filed 13 May 2022.